Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study

Diabetologia

Volumn 58, Issue 1, 2015, Pages 50-58

  Mogensen, Ulrik M ^a   Andersson, Charlotte ^b   Fosbøl, Emil L ^a   Schramm, Tina K ^c   Vaag, Allan ^a   Scheller, Nikolai M ^d   Torp Pedersen, Christian ^d   Gislason, Gunnar ^b,e,f   Køber, Lars ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular disease; Mortality; Risk; Treatment; Type 2 diabetes mellitus

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CEREBROVASCULAR ACCIDENT; DEATH; DENMARK; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGED; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHY; EPIDEMIOLOGY; REGISTER;

ADULT; AGED; DENMARK; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 84916602915     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3372-z     Document Type: Article

References (34)

1. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012
2. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30
3. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
4. Nathan DM (2002) Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342–1349
5. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR (2002) Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330–336
6. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ (1992) Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 15:953–959
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
8. Lebovitz HE, Pasmantier R (1990) Combination insulin-sulfonylurea therapy. Diabetes Care 13:667–675
9. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358:2630–2633
10. Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86:247–253
11. Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908
12. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389–394
13. Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
14. Gore MO, McGuire DK (2011) Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J 32:1832–1834
15. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
16. Olsen AM, Fosbol EL, Lindhardsen J et al (2013) Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients—a nationwide study. PLoS One 8:e54309
17. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83
18. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
19. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396
20. Lund SS, Tarnow L, Frandsen M et al (2009) Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 339:b4324
21. Salsburg DS (1971) The UGDP study. JAMA 218:1704–1705
22. Kahler KH, Rajan M, Rhoads GG et al (2007) Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30:1689–1693
23. Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731
24. Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157:601–610
25. Gribble FM, Reimann F (2003) Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat 17:11–15
26. Tomai F, Crea F, Gaspardone A et al (1994) Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 90:700–705
27. Klepzig H, Kober G, Matter C et al (1999) Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439–446
28. Maddock HL, Siedlecka SM, Yellon DM (2004) Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 18:113–119
29. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER (2008) No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 10:350–352
30. Andersson C, Gislason GH, Jorgensen CH et al (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 94:119–125
31. Groop LC, Groop PH, Stenman S (1990) Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care 13(Suppl 3):47–52
32. Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533
33. Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418
34. Bonds DE, Miller ME, Bergenstal RM et al (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909